Enrolled patients:~stage IIIB or stage IV NSCLC~Each center confirmed ALK+ by tissue samples (Abbott FISH, VENTANA ALK D5F3, NGS method confirmation);~Without any ALK-TKI treatment; Study endpoint~Primary endpoint:~According to the RECIST1.1 standard, the progression-free survival (PFS) assessed by the investigator;~Secondary endpoint:~According to the RECIST1.1 standard, the objective response rate (ORR) evaluated by the investigator; the time to treatment failure (TTF); according to the RECIST1.1 standard, the ORR and PFS of patients with different ALK fusion subtypes evaluated by the investigator; total Lifetime (OS); safety;~Exploratory endpoint:~The correlation between the biomarkers in blood or/and tissue samples and the efficacy of Ensatinib; the resistance mechanism of Ensatinib;~The sample size is determined:~The plan is to analyze 60-80 patients with EML4-ALK fusion v1 and v3 subtypes. Based on the proportion of patients with both subtypes in ALK-positive patients, the proportion is about 40%. Based on the 20% dropout rate, the plan is to include ALK without distinction. 180 patients with fusion subtype; statistical methods:
The experimental design is exploratory, single-arm, multi-center, real-world research.~Ensatinib 225mg qd A prospective and exploratory real-world study of Ensatinib for ALK-positive advanced non-small cell lung cancer patients Test purposes Exploring the real world, Ensatinib is effective for the newly treated ALK+ advanced NSCLC~Efficacy and safety;~The relationship between molecular mechanism and curative effect;~Ensatinib resistance mechanism;